Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality

PLoS Pathogens

Volumn 13, Issue 3, 2017, Pages

  Beauparlant, David ^a   Rusert, Peter ^a   Magnus, Carsten ^a,d   Kadelka, Claus ^a,b   Weber, Jacqueline ^a   Uhr, Therese ^a   Zagordi, Osvaldo ^a   Oberle, Corinna ^a,e   Duenas Decamp, Maria J ^c   Clapham, Paul R ^c   Metzner, Karin J ^a,b   Günthard, Huldrych F ^a,b   Trkola, Alexandra ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d SWISS FEDERAL INSTITUTE OF TECHNOLOGY   (Switzerland)

^e Gilead Sciences Switzerland Sarl   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; GLYCOPROTEIN GP 120; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL FUSION; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; STOICHIOMETRY; VIRAL TROPISM; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS TRANSMISSION; ADAPTATION; CELL SEPARATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MONONUCLEAR CELL; PATHOGENICITY; PHYSIOLOGY; VIROLOGY;

ADAPTATION, PHYSIOLOGICAL; ANTIGENS, CD4; CELL SEPARATION; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; VIRAL TROPISM; VIRUS INTERNALIZATION;

EID: 85016498505     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1006255     Document Type: Article

References (169)

1. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature. 2002;420(6916):678–82. doi: 10.1038/nature0118812478295
2. Weiss RA, Clapham PR, McClure MO, McKeating JA, McKnight A, Dalgleish AG, et al. Human immunodeficiency viruses: neutralization and receptors. Journal of acquired immune deficiency syndromes. 1988;1(6):536–41. Epub 1988/01/01. 2465401
3. Lynch RM, Tran L, Louder MK, Schmidt SD, Cohen M, Members CCT, et al. The development of CD4 binding site antibodies during HIV-1 infection. Journal of virology. 2012;86(14):7588–95. Epub 2012/05/11. doi: 10.1128/JVI.00734-1222573869
4. Georgiev IS, Gordon Joyce M, Zhou T, Kwong PD, Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site. Current opinion in HIV and AIDS. 2013;8(5):382–92. Epub 2013/08/09. doi: 10.1097/COH.0b013e328363a90e23924998
5. Grossman Z, Meier-Schellersheim M, Sousa AE, Victorino RM, Paul WE, CD4+ T-cell depletion in HIV infection: are we closer to understanding the cause?Nature medicine. 2002;8(4):319–23. Epub 2002/04/03. doi: 10.1038/nm0402-31911927927
6. Cooper A, Garcia M, Petrovas C, Yamamoto T, Koup RA, Nabel GJ, HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration. Nature. 2013;498(7454):376–9. Epub 2013/06/07. doi: 10.1038/nature1227423739328
7. Doitsh G, Galloway NL, Geng X, Yang Z, Monroe KM, Zepeda O, et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature. 2014;505(7484):509–14. Epub 2013/12/21. doi: 10.1038/nature1294024356306
8. Okoye AA, Picker LJ, CD4(+) T-cell depletion in HIV infection: mechanisms of immunological failure. Immunological reviews. 2013;254(1):54–64. Epub 2013/06/19. doi: 10.1111/imr.1206623772614
9. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature. 1993;362(6418):355–8. Epub 1993/03/25. doi: 10.1038/362355a08455722
10. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. The Journal of experimental medicine. 2004;200(6):749–59. Epub 2004/09/15. doi: 10.1084/jem.2004087415365096
11. Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. The Journal of experimental medicine. 2004;200(6):761–70. Epub 2004/09/15. doi: 10.1084/jem.2004119615365095
12. Doitsh G, Greene WC, Dissecting How CD4 T Cells Are Lost During HIV Infection. Cell host & microbe. 2016;19(3):280–91. Epub 2016/03/11.
13. Janaka SK, Gregory DA, Johnson MC, Retrovirus glycoprotein functionality requires proper alignment of the ectodomain and the membrane-proximal cytoplasmic tail. Journal of virology. 2013;87(23):12805–13. Epub 2013/09/21. doi: 10.1128/JVI.01847-1324049172
14. Duncan CJ, Sattentau QJ, Viral determinants of HIV-1 macrophage tropism. Viruses. 2011;3(11):2255–79. doi: 10.3390/v311225522163344
15. Berger EA, Murphy PM, Farber JM, Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annual review of immunology. 1999;17:657–700. Epub 1999/06/08. doi: 10.1146/annurev.immunol.17.1.65710358771
16. Mazurov D, Ilinskaya A, Heidecker G, Lloyd P, Derse D, Quantitative comparison of HTLV-1 and HIV-1 cell-to-cell infection with new replication dependent vectors. PLoS pathogens. 2010;6(2):e1000788. Epub 2010/03/03. doi: 10.1371/journal.ppat.100078820195464
17. Gorry PR, Sterjovski J, Churchill M, Witlox K, Gray L, Cunningham A, et al. The role of viral coreceptors and enhanced macrophage tropism in human immunodeficiency virus type 1 disease progression. Sexual health. 2004;1(1):23–34. Epub 2005/12/13. 16335478
18. Musich T, Peters PJ, Duenas-Decamp MJ, Gonzalez-Perez MP, Robinson J, Zolla-Pazner S, et al. A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection. Journal of virology. 2011;85(5):2397–405. Epub 2010/12/17. doi: 10.1128/JVI.02187-1021159865
19. Gorry PR, Zhang C, Wu S, Kunstman K, Trachtenberg E, Phair J, et al. Persistence of dual-tropic HIV-1 in an individual homozygous for the CCR5Δ32 allele. The Lancet. 2002;359(9320):1832–4.
20. Gorry PR, Taylor J, Holm GH, Mehle A, Morgan T, Cayabyab M, et al. Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. Journal of virology. 2002;76(12):6277–92. Epub 2002/05/22. doi: 10.1128/JVI.76.12.6277-6292.200212021361
21. Joseph SB, Arrildt KT, Swanstrom AE, Schnell G, Lee B, Hoxie JA, et al. Quantification of entry phenotypes of macrophage-tropic HIV-1 across a wide range of CD4 densities. Journal of virology. 2014;88(4):1858–69. Epub 2013/12/07. doi: 10.1128/JVI.02477-1324307580
22. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR, The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America. 1997;94(5):1925–30. 9050881
23. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA, The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 1984;312(5996):763–7. Epub 1984/12/20. 6096719
24. Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, Hercend T, et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature. 1984;312(5996):767–8. Epub 1984/12/20. 6083454
25. McDougal JS, Kennedy MS, Sligh JM, Cort SP, Mawle A, Nicholson JK, Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule. Science. 1986;231(4736):382–5. Epub 1986/01/24. 3001934
26. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996;381(6584):661–6. Epub 1996/06/20. doi: 10.1038/381661a08649511
27. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996;381(6584):667–73. Epub 1996/06/20. doi: 10.1038/381667a08649512
28. Feng Y, Broder CC, Kennedy PE, Berger EA, HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996;272(5263):872–7. Epub 1996/05/10.
29. Lee B, Sharron M, Montaner LJ, Weissman D, Doms RW, Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proceedings of the National Academy of Sciences of the United States of America. 1999;96(9):5215–20. Epub 1999/04/29. 10220446
30. Richardson MW, Jadlowsky J, Didigu CA, Doms RW, Riley JL, Kruppel-like factor 2 modulates CCR5 expression and susceptibility to HIV-1 infection. Journal of immunology. 2012;189(8):3815–21.
31. Wolfs TF, Zwart G, Bakker M, Goudsmit J, HIV-1 genomic RNA diversification following sexual and parenteral virus transmission. Virology. 1992;189(1):103–10. Epub 1992/07/01. 1376536
32. Scarlatti G, Tresoldi E, Bjorndal A, Fredriksson R, Colognesi C, Deng HK, et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nature medicine. 1997;3(11):1259–65. Epub 1997/11/14. 9359702
33. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(21):7552–7. Epub 2008/05/21. doi: 10.1073/pnas.080220310518490657
34. Chikere K, Webb NE, Chou T, Borm K, Sterjovski J, Gorry PR, et al. Distinct HIV-1 entry phenotypes are associated with transmission, subtype specificity, and resistance to broadly neutralizing antibodies. Retrovirology. 2014;11:48. Epub 2014/06/25. doi: 10.1186/1742-4690-11-4824957778
35. Blaak H, van't Wout AB, Brouwer M, Hooibrink B, Hovenkamp E, Schuitemaker H, In vivo HIV-1 infection of CD45RA(+)CD4(+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T cell decline. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(3):1269–74. Epub 2000/02/03. 10655520
36. Clapham PR, McKnight A, HIV-1 receptors and cell tropism. British medical bulletin. 2001;58:43–59. Epub 2001/11/21. 11714623
37. Tersmette M, Gruters RA, de Wolf F, de Goede RE, Lange JM, Schellekens PT, et al. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. Journal of virology. 1989;63(5):2118–25. Epub 1989/05/01. 2564898
38. Koot M, Keet IP, Vos AH, de Goede RE, Roos MT, Coutinho RA, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Annals of internal medicine. 1993;118(9):681–8. Epub 1993/05/01. 8096374
39. Shepherd JC, Jacobson LP, Qiao W, Jamieson BD, Phair JP, Piazza P, et al. Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study. The Journal of infectious diseases. 2008;198(8):1104–12. Epub 2008/09/12. doi: 10.1086/59162318783316
40. Simon B, Grabmeier-Pfistershammer K, Rieger A, Sarcletti M, Schmied B, Puchhammer-Stockl E, HIV coreceptor tropism in antiretroviral treatment-naive patients newly diagnosed at a late stage of HIV infection. AIDS. 2010;24(13):2051–8. Epub 2010/07/06. doi: 10.1097/QAD.0b013e32833c93e620601851
41. Wilkin TJ, Goetz MB, Leduc R, Skowron G, Su Z, Chan ES, et al. Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2011;52(7):925–8. Epub 2011/03/24.
42. Zhuang K, Finzi A, Toma J, Frantzell A, Huang W, Sodroski J, et al. Identification of interdependent variables that influence coreceptor switch in R5 SHIV(SF162P3N)-infected macaques. Retrovirology. 2012;9:106. Epub 2012/12/15. doi: 10.1186/1742-4690-9-10623237529
43. Zhuang K, Finzi A, Tasca S, Shakirzyanova M, Knight H, Westmoreland S, et al. Adoption of an "open" envelope conformation facilitating CD4 binding and structural remodeling precedes coreceptor switch in R5 SHIV-infected macaques. PloS one. 2011;6(7):e21350. Epub 2011/07/16. doi: 10.1371/journal.pone.002135021760891
44. Tersmette M, Lange JM, de Goede RE, de Wolf F, Eeftink-Schattenkerk JK, Schellekens PT, et al. Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet. 1989;1(8645):983–5. Epub 1989/05/06. 2565516
45. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van Steenwijk RP, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. Journal of virology. 1992;66(3):1354–60. Epub 1992/03/01. 1738194
46. Cashin K, Paukovics G, Jakobsen MR, Ostergaard L, Churchill MJ, Gorry PR, et al. Differences in coreceptor specificity contribute to alternative tropism of HIV-1 subtype C for CD4 + T-cell subsets, including stem cell memory T-cells. Retrovirology. 2014;11(1):97. Epub 2014/11/13.
47. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR, Change in coreceptor use correlates with disease progression in HIV-1--infected individuals. The Journal of experimental medicine. 1997;185(4):621–8. Epub 1997/02/17. 9034141
48. Connor RI, Mohri H, Cao Y, Ho DD, Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. Journal of virology. 1993;67(4):1772–7. Epub 1993/04/01. 8095306
49. Blaak H, Brouwer M, Ran LJ, de Wolf F, Schuitemaker H, In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection. The Journal of infectious diseases. 1998;177(3):600–10. Epub 1998/03/14. 9498438
50. Masciotra S, Owen SM, Rudolph D, Yang C, Wang B, Saksena N, et al. Temporal relationship between V1V2 variation, macrophage replication, and coreceptor adaptation during HIV-1 disease progression. AIDS. 2002;16(14):1887–98. Epub 2002/09/28. 12351948
51. Tuttle DL, Anders CB, Aquino-De Jesus MJ, Poole PP, Lamers SL, Briggs DR, et al. Increased replication of non-syncytium-inducing HIV type 1 isolates in monocyte-derived macrophages is linked to advanced disease in infected children. AIDS research and human retroviruses. 2002;18(5):353–62. doi: 10.1089/08892220275351913311897037
52. Repits J, Sterjovski J, Badia-Martinez D, Mild M, Gray L, Churchill MJ, et al. Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge. Virology. 2008;379(1):125–34. doi: 10.1016/j.virol.2008.06.01418672260
53. Duenas-Decamp MJ, Peters PJ, Repik A, Musich T, Gonzalez-Perez MP, Caron C, et al. Variation in the biological properties of HIV-1 R5 envelopes: implications of envelope structure, transmission and pathogenesis. Future virology. 2010;5(4):435–51. Epub 2010/10/12. doi: 10.2217/fvl.10.3420930940
54. Tsao LC, Guo H, Jeffrey J, Hoxie JA, Su L, CCR5 interaction with HIV-1 Env contributes to Env-induced depletion of CD4 T cells in vitro and in vivo. Retrovirology. 2016;13:22. doi: 10.1186/s12977-016-0255-z27026376
55. Parrish NF, Wilen CB, Banks LB, Iyer SS, Pfaff JM, Salazar-Gonzalez JF, et al. Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin alpha4beta7. PLoS pathogens. 2012;8(5):e1002686. Epub 2012/06/14. doi: 10.1371/journal.ppat.100268622693444
56. Moore JP, Kitchen SG, Pugach P, Zack JA, The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS research and human retroviruses. 2004;20(1):111–26. Epub 2004/03/06. doi: 10.1089/08892220432274956715000703
57. Meyaard L, Otto SA, Jonker RR, Mijnster MJ, Keet RP, Miedema F, Programmed death of T cells in HIV-1 infection. Science. 1992;257(5067):217–9. Epub 1992/07/10. 1352911
58. Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, Monks C, et al. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nature medicine. 1995;1(2):129–34. Epub 1995/02/01. 7585008
59. Perfettini JL, Castedo M, Roumier T, Andreau K, Nardacci R, Piacentini M, et al. Mechanisms of apoptosis induction by the HIV-1 envelope. Cell death and differentiation. 2005;12Suppl 1:916–23. Epub 2005/02/19.
60. Garg H, Mohl J, Joshi A, HIV-1 induced bystander apoptosis. Viruses. 2012;4(11):3020–43. Epub 2012/12/04. doi: 10.3390/v411302023202514
61. Gorry PR, Ancuta P, Coreceptors and HIV-1 pathogenesis. Current HIV/AIDS reports. 2011;8(1):45–53. Epub 2010/12/29. doi: 10.1007/s11904-010-0069-x21188555
62. Parker ZF, Iyer SS, Wilen CB, Parrish NF, Chikere KC, Lee FH, et al. Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. Journal of virology. 2013;87(5):2401–11. Epub 2012/12/28. doi: 10.1128/JVI.02964-1223269796
63. Martin J, LaBranche CC, Gonzalez-Scarano F, Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate. Journal of virology. 2001;75(8):3568–80. Epub 2001/03/27. doi: 10.1128/JVI.75.8.3568-3580.200111264346
64. Peters PJ, Bhattacharya J, Hibbitts S, Dittmar MT, Simmons G, Bell J, et al. Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusigenicity for macrophages. Journal of virology. 2004;78(13):6915–26. Epub 2004/06/15. doi: 10.1128/JVI.78.13.6915-6926.200415194768
65. Dunfee R, Thomas ER, Gorry PR, Wang J, Ancuta P, Gabuzda D, Mechanisms of HIV-1 neurotropism. Current HIV research. 2006;4(3):267–78. Epub 2006/07/18. 16842080
66. Thomas ER, Dunfee RL, Stanton J, Bogdan D, Taylor J, Kunstman K, et al. Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion. Virology. 2007;360(1):105–19. Epub 2006/11/07. doi: 10.1016/j.virol.2006.09.03617084877
67. Dunfee RL, Thomas ER, Wang J, Kunstman K, Wolinsky SM, Gabuzda D, Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia. Virology. 2007;367(1):222–34. Epub 2007/06/30. doi: 10.1016/j.virol.2007.05.02917599380
68. Gorry PR, Dunfee RL, Mefford ME, Kunstman K, Morgan T, Moore JP, et al. Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote. Virology. 2007;362(1):163–78. Epub 2007/01/24. doi: 10.1016/j.virol.2006.11.02517239419
69. Gorry PR, Bristol G, Zack JA, Ritola K, Swanstrom R, Birch CJ, et al. Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. Journal of virology. 2001;75(21):10073–89. Epub 2001/10/03. doi: 10.1128/JVI.75.21.10073-10089.200111581376
70. Gray L, Sterjovski J, Churchill M, Ellery P, Nasr N, Lewin SR, et al. Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome. Virology. 2005;337(2):384–98. Epub 2005/05/27. doi: 10.1016/j.virol.2005.04.03415916792
71. Sterjovski J, Roche M, Churchill MJ, Ellett A, Farrugia W, Gray LR, et al. An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes. Virology. 2010;404(2):269–78. Epub 2010/06/24. doi: 10.1016/j.virol.2010.05.00620570309
72. Dejucq N, Simmons G, Clapham PR, Expanded tropism of primary human immunodeficiency virus type 1 R5 strains to CD4(+) T-cell lines determined by the capacity to exploit low concentrations of CCR5. Journal of virology. 1999;73(9):7842–7. Epub 1999/08/10. 10438877
73. Gray LR, Turville SG, Hitchen TL, Cheng WJ, Ellett AM, Salimi H, et al. HIV-1 entry and trans-infection of astrocytes involves CD81 vesicles. PloS one. 2014;9(2):e90620. Epub 2014/03/04. doi: 10.1371/journal.pone.009062024587404
74. Gorry PR, Francella N, Lewin SR, Collman RG, HIV-1 envelope-receptor interactions required for macrophage infection and implications for current HIV-1 cure strategies. Journal of leukocyte biology. 2014;95(1):71–81. Epub 2013/10/26. doi: 10.1189/jlb.071336824158961
75. Schweizer A, Rusert P, Berlinger L, Ruprecht CR, Mann A, Corthesy S, et al. CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics. PLoS pathogens. 2008;4(7):e1000109. Epub 2008/07/26. doi: 10.1371/journal.ppat.100010918654624
76. Peters PJ, Sullivan WM, Duenas-Decamp MJ, Bhattacharya J, Ankghuambom C, Brown R, et al. Non-macrophage-tropic human immunodeficiency virus type 1 R5 envelopes predominate in blood, lymph nodes, and semen: implications for transmission and pathogenesis. Journal of virology. 2006;80(13):6324–32. Epub 2006/06/16. doi: 10.1128/JVI.02328-0516775320
77. Peters PJ, Duenas-Decamp MJ, Sullivan WM, Clapham PR, Variation of macrophage tropism among HIV-1 R5 envelopes in brain and other tissues. Journal of neuroimmune pharmacology: the official journal of the Society on NeuroImmune Pharmacology. 2007;2(1):32–41. Epub 2007/11/28.
78. Peters PJ, Duenas-Decamp MJ, Sullivan WM, Brown R, Ankghuambom C, Luzuriaga K, et al. Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors. Retrovirology. 2008;5:5. Epub 2008/01/22. doi: 10.1186/1742-4690-5-518205925
79. Duenas-Decamp MJ, Peters PJ, Burton D, Clapham PR, Determinants flanking the CD4 binding loop modulate macrophage tropism of human immunodeficiency virus type 1 R5 envelopes. Journal of virology. 2009;83(6):2575–83. Epub 2009/01/09. doi: 10.1128/JVI.02133-0819129457
80. Richards KH, Aasa-Chapman MM, McKnight A, Clapham PR, Modulation of HIV-1 macrophage-tropism among R5 envelopes occurs before detection of neutralizing antibodies. Retrovirology. 2010;7:48. Epub 2010/05/29. doi: 10.1186/1742-4690-7-4820507591
81. Dunfee RL, Thomas ER, Gorry PR, Wang J, Taylor J, Kunstman K, et al. The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(41):15160–5. Epub 2006/10/04. doi: 10.1073/pnas.060551310317015824
82. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nature medicine. 2005;11(6):615–22. Epub 2005/05/10. doi: 10.1038/nm124415880120
83. Rusert P, Kuster H, Joos B, Misselwitz B, Gujer C, Leemann C, et al. Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. Journal of virology. 2005;79(13):8454–69. Epub 2005/06/16. doi: 10.1128/JVI.79.13.8454-8469.200515956589
84. Manrique A, Rusert P, Joos B, Fischer M, Kuster H, Leemann C, et al. In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. Journal of virology. 2007;81(16):8793–808. doi: 10.1128/JVI.00598-0717567707
85. Neumann T, Hagmann I, Lohrengel S, Heil ML, Derdeyn CA, Krausslich HG, et al. T20-insensitive HIV-1 from naive patients exhibits high viral fitness in a novel dual-color competition assay on primary cells. Virology. 2005;333(2):251–62. Epub 2005/02/22. doi: 10.1016/j.virol.2004.12.03515721359
86. Allaway GP, Davis-Bruno KL, Beaudry GA, Garcia EB, Wong EL, Ryder AM, et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS research and human retroviruses. 1995;11(5):533–9. Epub 1995/05/01. doi: 10.1089/aid.1995.11.5337576908
87. Pugach P, Kuhmann SE, Taylor J, Marozsan AJ, Snyder A, Ketas T, et al. The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. Virology. 2004;321(1):8–22. Epub 2004/03/23. doi: 10.1016/j.virol.2003.12.01215033560
88. Beaumont T, Quakkelaar E, van Nuenen A, Pantophlet R, Schuitemaker H, Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker. Journal of virology. 2004;78(11):5651–7. doi: 10.1128/JVI.78.11.5651-5657.200415140962
89. Moore JP, Burkly LC, Connor RI, Cao Y, Tizard R, Ho DD, et al. Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4. AIDS research and human retroviruses. 1993;9(6):529–39. Epub 1993/06/01. doi: 10.1089/aid.1993.9.5298347397
90. Chikere K, Chou T, Gorry PR, Lee B, Affinofile profiling: how efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIV. Virology. 2013;435(1):81–91. Epub 2012/12/12. doi: 10.1016/j.virol.2012.09.04323217618
91. Johnston SH, Lobritz MA, Nguyen S, Lassen K, Delair S, Posta F, et al. A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains. Journal of virology. 2009;83(21):11016–26. Epub 2009/08/21. doi: 10.1128/JVI.01242-0919692480
92. Salimi H, Roche M, Webb N, Gray LR, Chikere K, Sterjovski J, et al. Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5. Journal of leukocyte biology. 2013;93(1):113–26. Epub 2012/10/19. doi: 10.1189/jlb.061230823077246
93. Schnell G, Joseph S, Spudich S, Price RW, Swanstrom R, HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS pathogens. 2011;7(10):e1002286. doi: 10.1371/journal.ppat.100228622007152
94. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D, Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. Journal of virology. 1998;72(4):2855–64. Epub 1998/04/03. 9525605
95. Reh L, Magnus C, Schanz M, Weber J, Uhr T, Rusert P, et al. Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent. PLoS pathogens. 2015;11(7):e1004966. Epub 2015/07/15. doi: 10.1371/journal.ppat.100496626158270
96. Ruprecht CR, Krarup A, Reynell L, Mann AM, Brandenberg OF, Berlinger L, et al. MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. The Journal of experimental medicine. 2011;208(3):439–54. Epub 2011/03/02. doi: 10.1084/jem.2010190721357743
97. Zhang S, Alexander L, Wang T, Agler M, Zhou N, Fang H, et al. Protection against HIV-envelope-induced neuronal cell destruction by HIV attachment inhibitors. Archives of virology. 2010;155(5):777–81. Epub 2010/03/20. doi: 10.1007/s00705-010-0644-x20300783
98. O'Connell O, Repik A, Reeves JD, Gonzalez-Perez MP, Quitadamo B, Anton ED, et al. Efficiency of bridging-sheet recruitment explains HIV-1 R5 envelope glycoprotein sensitivity to soluble CD4 and macrophage tropism. Journal of virology. 2013;87(1):187–98. Epub 2012/10/12. doi: 10.1128/JVI.01834-1223055568
99. Sterjovski J, Churchill MJ, Roche M, Ellett A, Farrugia W, Wesselingh SL, et al. CD4-binding site alterations in CCR5-using HIV-1 envelopes influencing gp120-CD4 interactions and fusogenicity. Virology. 2011;410(2):418–28. Epub 2011/01/11. doi: 10.1016/j.virol.2010.12.01021216423
100. Stewart-Jones GB, Soto C, Lemmin T, Chuang GY, Druz A, Kong R, et al. Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G. Cell. 2016;165(4):813–26. doi: 10.1016/j.cell.2016.04.01027114034
101. Schrodinger L. The PyMOL Molecular Graphics System, Version 1.4.1 2015.
102. Holman AG, Mefford ME, O'Connor N, Gabuzda D, HIVBrainSeqDB: a database of annotated HIV envelope sequences from brain and other anatomical sites. AIDS research and therapy. 2010;7:43. Epub 2010/12/16. doi: 10.1186/1742-6405-7-4321156070
103. Xiang SH, Finzi A, Pacheco B, Alexander K, Yuan W, Rizzuto C, et al. A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer. Journal of virology. 2010;84(7):3147–61. Epub 2010/01/22. doi: 10.1128/JVI.02587-0920089638
104. Huang X, Jin W, Hu K, Luo S, Du T, Griffin GE, et al. Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction. Virology. 2012;423(1):97–106. doi: 10.1016/j.virol.2011.11.02322192629
105. Wang W, Nie J, Prochnow C, Truong C, Jia Z, Wang S, et al. A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization. Retrovirology. 2013;10:14. Epub 2013/02/07. doi: 10.1186/1742-4690-10-1423384254
106. Kolchinsky P, Mirzabekov T, Farzan M, Kiprilov E, Cayabyab M, Mooney LJ, et al. Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication. Journal of virology. 1999;73(10):8120–6. Epub 1999/09/11. 10482561
107. Kolchinsky P, Kiprilov E, Bartley P, Rubinstein R, Sodroski J, Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops. Journal of virology. 2001;75(7):3435–43. Epub 2001/03/10. doi: 10.1128/JVI.75.7.3435-3443.200111238869
108. Mefford ME, Gorry PR, Kunstman K, Wolinsky SM, Gabuzda D, Bioinformatic prediction programs underestimate the frequency of CXCR4 usage by R5X4 HIV type 1 in brain and other tissues. AIDS research and human retroviruses. 2008;24(9):1215–20. Epub 2008/09/16. doi: 10.1089/aid.2008.000918788913
109. Byland R, Vance PJ, Hoxie JA, Marsh M, A conserved dileucine motif mediates clathrin and AP-2-dependent endocytosis of the HIV-1 envelope protein. Mol Biol Cell. 2007;18(2):414–25. doi: 10.1091/mbc.E06-06-053517108326
110. Mann A, Friedrich N, Krarup A, Weber J, Stiegeler E, Dreier B, et al. Conformation-dependent recognition of HIV gp120 by designed ankyrin repeat proteins provides access to novel HIV entry inhibitors. Journal of virology. 2013;87(10):5868–81. Epub 2013/03/15. doi: 10.1128/JVI.00152-1323487463
111. Magnus C, Regoes RR, Estimating the stoichiometry of HIV neutralization. PLoS Comput Biol. 2010;6(3):e1000713. doi: 10.1371/journal.pcbi.100071320333245
112. Brandenberg OF, Magnus C, Rusert P, Regoes RR, Trkola A, Different infectivity of HIV-1 strains is linked to number of envelope trimers required for entry. PLoS pathogens. 2015;11(1):e1004595. Epub 2015/01/09. doi: 10.1371/journal.ppat.100459525569556
113. Brandenberg OF, Magnus C, Regoes RR, Trkola A, The HIV-1 Entry Process: A Stoichiometric View. Trends in microbiology. 2015;23(12):763–74. Epub 2015/11/07. doi: 10.1016/j.tim.2015.09.00326541228
114. Magnus C, Rusert P, Bonhoeffer S, Trkola A, Regoes RR, Estimating the stoichiometry of human immunodeficiency virus entry. Journal of virology. 2009;83(3):1523–31. Epub 2008/11/21. doi: 10.1128/JVI.01764-0819019953
115. Ping LH, Joseph SB, Anderson JA, Abrahams MR, Salazar-Gonzalez JF, Kincer LP, et al. Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. Journal of virology. 2013;87(13):7218–33. Epub 2013/04/26. doi: 10.1128/JVI.03577-1223616655
116. Biancotto A, Iglehart SJ, Vanpouille C, Condack CE, Lisco A, Ruecker E, et al. HIV-1-induced activation of CD4(+) T cells creates new targets for HIV-1 infection in human lymphoid tissue ex vivo. Blood. 2008;111(2):699–704. doi: 10.1182/blood-2007-05-08843517909079
117. Gray L, Roche M, Churchill MJ, Sterjovski J, Ellett A, Poumbourios P, et al. Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain. Journal of virology. 2009;83(11):5430–41. Epub 2009/03/27. doi: 10.1128/JVI.02648-0819321618
118. Gorry P, Purcell D, Howard J, McPhee D, Restricted HIV-1 infection of human astrocytes: potential role of nef in the regulation of virus replication. Journal of neurovirology. 1998;4(4):377–86. Epub 1998/08/26. 9718129
119. Ellery PJ, Tippett E, Chiu YL, Paukovics G, Cameron PU, Solomon A, et al. The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. Journal of immunology. 2007;178(10):6581–9. Epub 2007/05/04.
120. Verhofstede C, Nijhuis M, Vandekerckhove L, Correlation of coreceptor usage and disease progression. Current opinion in HIV and AIDS. 2012;7(5):432–9. Epub 2012/08/09. doi: 10.1097/COH.0b013e328356f6f222871636
121. Pollakis G, Paxton WA, Use of (alternative) coreceptors for HIV entry. Current opinion in HIV and AIDS. 2012;7(5):440–9. doi: 10.1097/COH.0b013e328356e9f322842622
122. Price RW, Neurological complications of HIV infection. The Lancet. 1996;348(9025):445–52.
123. Dunfee RL, Thomas ER, Gabuzda D, Enhanced macrophage tropism of HIV in brain and lymphoid tissues is associated with sensitivity to the broadly neutralizing CD4 binding site antibody b12. Retrovirology. 2009;6:69. Epub 2009/07/22. doi: 10.1186/1742-4690-6-6919619305
124. Churchill MJ, Cowley DJ, Wesselingh SL, Gorry PR, Gray LR, HIV-1 transcriptional regulation in the central nervous system and implications for HIV cure research. Journal of neurovirology. 2014. Epub 2014/07/26.
125. Arrildt KT, LaBranche CC, Joseph SB, Dukhovlinova EN, Graham WD, Ping LH, et al. Phenotypic Correlates of HIV-1 Macrophage Tropism. Journal of virology. 2015;89(22):11294–311. Epub 2015/09/05. doi: 10.1128/JVI.00946-1526339058
126. Musich T, O'Connell O, Gonzalez-Perez MP, Derdeyn CA, Peters PJ, Clapham PR, HIV-1 non-macrophage-tropic R5 envelope glycoproteins are not more tropic for entry into primary CD4+ T-cells than envelopes highly adapted for macrophages. Retrovirology. 2015;12:25. Epub 2015/03/27. doi: 10.1186/s12977-015-0141-025809903
127. Mefford ME, Kunstman K, Wolinsky SM, Gabuzda D, Bioinformatic analysis of neurotropic HIV envelope sequences identifies polymorphisms in the gp120 bridging sheet that increase macrophage-tropism through enhanced interactions with CCR5. Virology. 2015;481:210–22. Epub 2015/03/24. doi: 10.1016/j.virol.2015.01.03225797607
128. Sattentau QJ, Stevenson M, Macrophages and HIV-1: An Unhealthy Constellation. Cell host & microbe. 2016;19(3):304–10. Epub 2016/03/11.
129. Joseph SB, Arrildt KT, Sturdevant CB, Swanstrom R, HIV-1 target cells in the CNS. Journal of neurovirology. 2015;21(3):276–89. Epub 2014/09/23. doi: 10.1007/s13365-014-0287-x25236812
130. Herschhorn A, Ma X, Gu C, Ventura JD, Castillo-Menendez L, Melillo B, et al. Release of gp120 Restraints Leads to an Entry-Competent Intermediate State of the HIV-1 Envelope Glycoproteins. mBio. 2016;7(5). Epub 2016/11/01.
131. Abela IA, Berlinger L, Schanz M, Reynell L, Gunthard HF, Rusert P, et al. Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS pathogens. 2012;8(4):e1002634. Epub 2012/04/13. doi: 10.1371/journal.ppat.100263422496655
132. Brandenberg OF, Rusert P, Magnus C, Weber J, Boni J, Gunthard HF, et al. Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation. Retrovirology. 2014;11:75. Epub 2014/10/08. doi: 10.1186/s12977-014-0075-y25287422
133. Clavel F, Charneau P, Fusion from without directed by human immunodeficiency virus particles. Journal of virology. 1994;68(2):1179–85. 8289347
134. Joseph SB, Swanstrom R, Kashuba AD, Cohen MS, Bottlenecks in HIV-1 transmission: insights from the study of founder viruses. Nature reviews Microbiology. 2015;13(7):414–25. Epub 2015/06/09. doi: 10.1038/nrmicro347126052661
135. Carlson JM, Schaefer M, Monaco DC, Batorsky R, Claiborne DT, Prince J, et al. HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneck. Science. 2014;345(6193):1254031. Epub 2014/07/12. doi: 10.1126/science.125403125013080
136. Sturdevant CB, Joseph SB, Schnell G, Price RW, Swanstrom R, Spudich S, Compartmentalized replication of R5 T cell-tropic HIV-1 in the central nervous system early in the course of infection. PLoS pathogens. 2015;11(3):e1004720. doi: 10.1371/journal.ppat.100472025811757
137. Ivey NS, MacLean AG, Lackner AA, Acquired immunodeficiency syndrome and the blood-brain barrier. Journal of neurovirology. 2009;15(2):111–22. doi: 10.1080/1355028090276976419306229
138. Mutnal MB, Hu S, Lokensgard JR, Persistent humoral immune responses in the CNS limit recovery of reactivated murine cytomegalovirus. PloS one. 2012;7(3):e33143. doi: 10.1371/journal.pone.003314322412996
139. Ousman SS, Kubes P, Immune surveillance in the central nervous system. Nat Neurosci. 2012;15(8):1096–101. doi: 10.1038/nn.316122837040
140. Ransohoff RM, Engelhardt B, The anatomical and cellular basis of immune surveillance in the central nervous system. Nature reviews Immunology. 2012;12(9):623–35. doi: 10.1038/nri326522903150
141. Bonnan M, Barroso B, Demasles S, Krim E, Marasescu R, Miquel M, Compartmentalized intrathecal immunoglobulin synthesis during HIV infection—a model of chronic CNS inflammation?J Neuroimmunol. 2015;285:41–52. doi: 10.1016/j.jneuroim.2015.05.01526198917
142. Bruno CJ, Jacobson JM, Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection. The Journal of antimicrobial chemotherapy. 2010;65(9):1839–41. doi: 10.1093/jac/dkq26120639524
143. Fessel WJ, Anderson B, Follansbee SE, Winters MA, Lewis ST, Weinheimer SP, et al. The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment. Antiviral research. 2011;92(3):484–7. doi: 10.1016/j.antiviral.2011.09.01022001594
144. Schols D, Baba M, Pauwels R, Desmyter J, De Clercq E, Specific interaction of aurintricarboxylic acid with the human immunodeficiency virus/CD4 cell receptor. Proceedings of the National Academy of Sciences of the United States of America. 1989;86(9):3322–6. 2566170
145. Pegu A, Yang ZY, Boyington JC, Wu L, Ko SY, Schmidt SD, et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med. 2014;6(243):243ra88. Epub 2014/07/06. doi: 10.1126/scitranslmed.300899224990883
146. Jacobson JM, Israel RJ, Lowy I, Ostrow NA, Vassilatos LS, Barish M, et al. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother. 2004;48(2):423–9. doi: 10.1128/AAC.48.2.423-429.200414742190
147. Jacobson JM, Lowy I, Fletcher CV, O'Neill TJ, Tran DN, Ketas TJ, et al. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. The Journal of infectious diseases. 2000;182(1):326–9. doi: 10.1086/31569810882617
148. Richard J, Veillette M, Brassard N, Iyer SS, Roger M, Martin L, et al. CD4 mimetics sensitize HIV-1-infected cells to ADCC. Proceedings of the National Academy of Sciences of the United States of America. 2015;112(20):E2687–94. doi: 10.1073/pnas.150675511225941367
149. Selhorst P, Grupping K, Tong T, Crooks ET, Martin L, Vanham G, et al. M48U1 CD4 mimetic has a sustained inhibitory effect on cell-associated HIV-1 by attenuating virion infectivity through gp120 shedding. Retrovirology. 2013;10:12. doi: 10.1186/1742-4690-10-1223375046
150. Haim H, Si Z, Madani N, Wang L, Courter JR, Princiotto A, et al. Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS pathogens. 2009;5(4):e1000360. doi: 10.1371/journal.ppat.100036019343205
151. Stricher F, Huang CC, Descours A, Duquesnoy S, Combes O, Decker JM, et al. Combinatorial optimization of a CD4-mimetic miniprotein and cocrystal structures with HIV-1 gp120 envelope glycoprotein. Journal of molecular biology. 2008;382(2):510–24. doi: 10.1016/j.jmb.2008.06.06918619974
152. Gardner MR, Kattenhorn LM, Kondur HR, von Schaewen M, Dorfman T, Chiang JJ, et al. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature. 2015;519(7541):87–91. doi: 10.1038/nature1426425707797
153. Moore JP, Stevenson M, New targets for inhibitors of HIV-1 replication. Nat Rev Mol Cell Biol. 2000;1(1):40–9. doi: 10.1038/3503606011413488
154. Klasse PJ, McKeating JA, Soluble CD4 and CD4 immunoglobulin-selected HIV-1 variants: a phenotypic characterization. AIDS research and human retroviruses. 1993;9(7):595–604. doi: 10.1089/aid.1993.9.5958369164
155. Lynch RM, Wong P, Tran L, O'Dell S, Nason MC, Li Y, et al. HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies. Journal of virology. 2015;89(8):4201–13. Epub 2015/01/30. doi: 10.1128/JVI.03608-1425631091
156. Rieder P, Joos B, von Wyl V, Kuster H, Grube C, Leemann C, et al. HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. AIDS. 2010;24(8):1177–83. Epub 2010/04/14. doi: 10.1097/QAD.0b013e328338e4de20386427
157. Oxenius A, Price DA, Gunthard HF, Dawson SJ, Fagard C, Perrin L, et al. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(21):13747–52. Epub 2002/10/09. doi: 10.1073/pnas.20237219912370434
158. Oxenius A, McLean AR, Fischer M, Price DA, Dawson SJ, Hafner R, et al. Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy. Journal of virology. 2002;76(20):10169–76. Epub 2002/09/20. 12239291
159. Fagard C, Oxenius A, Gunthard H, Garcia F, Le Braz M, Mestre G, et al. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Archives of internal medicine. 2003;163(10):1220–6. Epub 2003/05/28. doi: 10.1001/archinte.163.10.122012767960
160. Swiss HIVCSSchoeni-Affolter F, Ledergerber B, Rickenbach M, Rudin C, Gunthard HF, et al. Cohort profile: the Swiss HIV Cohort study. International journal of epidemiology. 2010;39(5):1179–89. Epub 2009/12/02. doi: 10.1093/ije/dyp32119948780
161. Platt EJ, Madani N, Kozak SL, Kabat D, Infectious properties of human immunodeficiency virus type 1 mutants with distinct affinities for the CD4 receptor. Journal of virology. 1997;71(2):883–90. Epub 1997/02/01. 8995604
162. Mann AM, Rusert P, Berlinger L, Kuster H, Gunthard HF, Trkola A, HIV sensitivity to neutralization is determined by target and virus producer cell properties. AIDS. 2009;23(13):1659–67. Epub 2009/07/08. doi: 10.1097/QAD.0b013e32832e940819581791
163. Rusert P, Mann A, Huber M, von Wyl V, Gunthard HF, Trkola A, Divergent effects of cell environment on HIV entry inhibitor activity. AIDS. 2009;23(11):1319–27. Epub 2009/07/07. 19579289
164. Zhong P, Agosto LM, Ilinskaya A, Dorjbal B, Truong R, Derse D, et al. Cell-to-cell transmission can overcome multiple donor and target cell barriers imposed on cell-free HIV. PloS one. 2013;8(1):e53138. Epub 2013/01/12. doi: 10.1371/journal.pone.005313823308151
165. Hamilton JA, Colony-stimulating factors in inflammation and autoimmunity. Nature reviews Immunology. 2008;8(7):533–44. Epub 2008/06/14. doi: 10.1038/nri235618551128
166. Young DA, L L, Clark SC, Comparison of the effects of IL-3, granulocyte-macrophage colony-stimulating factor, and macrophage colony-stimulating factor in supporting monocyte differentiation in culture. Analysis of macrophage antibody-dependent cellular cytotoxicity. The Journal of Immunology. 1990;145(2):607–15. Epub n/a. 2142182
167. Vogel DY, Glim JE, Stavenuiter AW, Breur M, Heijnen P, Amor S, et al. Human macrophage polarization in vitro: Maturation and activation methods compared. Immunobiology. 2014;219(9):695–703. Epub 2014/06/12. doi: 10.1016/j.imbio.2014.05.00224916404
168. Ambarus CA, Krausz S, van Eijk M, Hamann J, Radstake TR, Reedquist KA, et al. Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. Journal of immunological methods. 2012;375(1–2):196–206. Epub 2011/11/15. doi: 10.1016/j.jim.2011.10.01322075274
169. Miyauchi K, Kozlov MM, Melikyan GB, Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation. PLoS pathogens. 2009;5(9):e1000585. Epub 2009/09/19. doi: 10.1371/journal.ppat.100058519763181